Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - sodium sulfate, quantity: 7.5 g; macrogol 3350, quantity: 100 g; potassium chloride, quantity: 1.015 g; ascorbic acid, quantity: 4.7 g; sodium ascorbate, quantity: 5.9 g; sodium chloride, quantity: 2.691 g - powder - excipient ingredients: acesulfame potassium; aspartame; flavour - for bowel cleansing prior to any clinical procedure requiring a clean bowel e.g. bowel endoscopy, lower gastrointestinal tract radiology or digestive tract surgery.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - ascorbic acid, quantity: 4.7 g; sodium chloride, quantity: 2.691 g; sodium sulfate, quantity: 7.5 g; potassium chloride, quantity: 1.015 g; macrogol 3350, quantity: 100 g; sodium ascorbate, quantity: 5.9 g - powder - excipient ingredients: acesulfame potassium; aspartame; flavour - for bowel cleansing prior to any clinical procedure requiring a clean bowel e.g. bowel endoscopy, lower gastrointestinal tract radiology or digestive tract surgery.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - valganciclovir, quantity: 5 g - solution, powder for - excipient ingredients: mannitol; fumaric acid; sodium benzoate; saccharin sodium; povidone; flavour - valcyte is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids). valcyte is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: benzoic acid; glycerol; citric acid; sodium chloride; purified water; sodium citrate dihydrate; propylene glycol; xylitol; sodium cyclamate; microcrystalline cellulose; carmellose sodium; flavour - treatment of chronic cholestatic liver diseases.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: purified water; sodium cyclamate; citric acid; sodium citrate dihydrate; xylitol; sodium chloride; glycerol; propylene glycol; benzoic acid; microcrystalline cellulose; carmellose sodium; flavour - treatment of chronic cholestatic liver diseases.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - riluzole, quantity: 0.5 g - oral liquid, suspension - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); aluminium magnesium silicate; xanthan gum; saccharin sodium; sodium lauryl sulfate; ceteareth-25; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - riluzole is indicated for the treatment of patients with amyotrophic lateral sclerosis (als).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenytoin, quantity: 6 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; polysorbate 40; citric acid monohydrate; glycerol; purified water; carmellose sodium; ethanol; vanillin; carmoisine; sucrose; sunset yellow fcf; aluminium magnesium silicate; flavour - dilantin is indicated for the control of grand mal and psychomotor seizures. dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, dilantin frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that dilantin is valuable in the prevention of seizures occurring during or after neurosurgery and in the treatment of certain cardiac arrythmias. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - sodium picosulfate, quantity: 10.3 mg; magnesium carbonate hydrate, quantity: 7.4002 g; citric acid, quantity: 12.1647 g - solution, powder for - excipient ingredients: steviol glycosides; flavour - bowel emptying and cleansing by means of total gastrointestinal tract perfusion in preparation for gastrointestinal examination (such as colonoscopy, barium enema x-ray examination), prior to intravenous pyelograms (ivp), or colorectal surgery, in adults and children 9 years of age and over.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - potassium chloride, quantity: 739 mg; sodium chloride, quantity: 2.613 g; sodium sulfate, quantity: 5.643 g; macrogol 3350, quantity: 52.898 g - solution, powder for - excipient ingredients: ascorbic acid; steviol glycosides; silicon dioxide; flavour - bowel emptying and cleansing by means of total gastrointestinal tract perfusion in preparation for gastrointestinal examination (such as colonoscopy, barium enema x-ray examination), prior to intravenous pyelograms (ivp) or colorectal surgery.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - magnesium carbonate hydrate, quantity: 7.4002 g; sodium picosulfate, quantity: 10.3 mg; citric acid, quantity: 12.1647 g - solution, powder for - excipient ingredients: steviol glycosides; flavour - bowel emptying and cleansing by means of total gastrointestinal tract perfusion in preparation for gastrointestinal examination (such as colonoscopy, barium enema x-ray examination), prior to intravenous pyelograms (ivp) or colorectal surgery, in adults and children 9 years of age and over.